Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy‐generated vaccine
Authors:
Open Access
- 2 May 2016
- journal article
- tumor immunology-and-microenvironment
- Published by Wiley in International Journal of Cancer
- Vol. 139 (6) , 1372-1378
Abstract
Acid ceramidase has been identified as a promising target for cancer therapy. One of its most effective inhibitors, LCL521, was examined as adjuvant to photodynamic therapy (PDT) using mouse squamous cell carcinoma SCCVII model of head and neck cancer. Lethal effects of PDT, assessed by colony forming ability of in vitro treated SCCVII cells, were greatly enhanced when combined with 10 µM LCL521 treatment particularly when preceding PDT. When PDT‐treated SCCVII cells are used to vaccinate SCCVII tumor‐bearing mice (PDT vaccine protocol), adjuvant LCL521 treatment (75 mg/kg) resulted in a marked retardation of tumor growth. This effect can be attributed to the capacity of LCL521 to effectively restrict the activity of two main immunoregulatory cell populations (Tregs and myeloid‐derived suppressor cells, MDSCs) that are known to hinder the efficacy of PDT vaccines. The therapeutic benefit with adjuvant LCL521 was also achieved with SCCVII tumors treated with standard PDT when using immunocompetent mice but not with immunodeficient hosts. The interaction of LCL521 with PDT‐based antitumor mechanisms is dominated by immune system contribution that includes overriding the effects of immunoregulatory cells, but could also include a tacit contribution from boosting direct tumor cell kill.Keywords
Funding Information
- Canadian Cancer Society (701132)
- Universiteit Stellenbosch (R01 CA77475, IPO1CA097132)
This publication has 45 references indexed in Scilit:
- Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapseJournal of Clinical Investigation, 2013
- Acid Ceramidase (ASAH1) Represses Steroidogenic Factor 1-Dependent Gene Transcription in H295R Human Adrenocortical Cells by Binding to the ReceptorMolecular and Cellular Biology, 2012
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathThe EMBO Journal, 2012
- Sphingosine regulates the NLRP3‐inflammasome and IL‐1β release from macrophagesEuropean Journal of Immunology, 2011
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- The outs and the ins of sphingosine-1-phosphate in immunityNature Reviews Immunology, 2011
- The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cellsNature Immunology, 2010
- Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapyExpert Opinion on Therapeutic Targets, 2009
- Novel analogs of d-e-MAPP and B13. Part 1: Synthesis and evaluation as potential anticancer agentsBioorganic & Medicinal Chemistry, 2008
- A house divided: Ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell deathBiochimica et Biophysica Acta (BBA) - Biomembranes, 2006